Aisling Capital Management LP — 13F Holdings & Portfolio
CIK 1766721 · latest 13F-HR filed 2026-05-05
Aisling Capital Management LP manages $476.3M in 13F-reported U.S. long-equity assets across 13 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are BBIO (79.35%), SNDX (6.46%), GLUE (5.37%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 1, added to 8, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$476.3M
Long-equity book
13
Distinct positions
2026-03-31
Filed 2026-05-05
+1 / −1 / ↑8 / ↓2
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Syndax Pharmaceuticals, Inc. (SNDX)$3.1M +11.2%
- Monte Rosa Therapeutics Inc (GLUE)$2.5M +10.8%
- BridgeBio Oncology Therapeutics (BBOT)$2.0M +28.9%
- Bicara Therapeutics Inc. (BCAX)$1.7M +18.2%
- Biomea Fusion Inc (BMEA)$594.1K +23.4%
Top Trims
- Urogen Pharma Ltd. (URGN)-$587.5K -23.2%
- Marker Therapeutics, Inc. (MRKR)-$61.8K -12.8%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 10806X102 | $378.0M | 79.35% | 5,089,611 | SH |
| 2 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 87164F105 | $30.8M | 6.46% | 1,316,806 | SH |
| 3 | Monte Rosa Therapeutics Inc (GLUE) | GLUE | 61225M102 | $25.6M | 5.37% | 1,555,664 | SH |
| 4 | Bicara Therapeutics Inc. (BCAX) | BCAX | 055477103 | $11.3M | 2.38% | 568,919 | SH |
| 5 | BridgeBio Oncology Therapeutics (BBOT) | BBOT | 107924102 | $9.1M | 1.91% | 1,018,018 | SH |
| 6 | Compass Pathways Plc (CMPS) | CMPS | 20451W101 | $7.9M | 1.66% | 1,432,336 | SH |
| 7 | Scholar Rock Holding Corporation (SRRK) | SRRK | 80706P103 | $3.8M | 0.80% | 77,031 | SH |
| 8 | Biomea Fusion Inc (BMEA) | BMEA | 09077A106 | $3.1M | 0.66% | 2,048,757 | SH |
| 9 | Eupraxia Pharmaceuticals Inc. (EPRX) | EPRX | 29842P105 | $2.4M | 0.49% | 325,000 | SH |
| 10 | Urogen Pharma Ltd. (URGN) | URGN | M96088105 | $1.9M | 0.41% | 108,000 | SH |
| 11 | Aclaris Therapeutics Inc (ACRS) | ACRS | 00461U105 | $1.6M | 0.34% | 434,455 | SH |
| 12 | Marker Therapeutics, Inc. (MRKR) | MRKR | 57055L206 | $423.0K | 0.09% | 325,370 | SH |
| 13 | OnKure Therapeutics, Inc. (OKUR) | OKUR | 68277Q105 | $366.8K | 0.08% | 88,607 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | $476.3M | 13 | 0001766721-26-000002 |
| 2025-12-31 | 2026-02-10 | $478.9M | 13 | 0001766721-26-000001 |